Suppr超能文献

帕金森病的神经精神医学:进展与挑战。

The neuropsychiatry of Parkinson's disease: advances and challenges.

机构信息

Departments of Psychiatry and Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parkinson's Disease Research, Education and Clinical Center, Corporal Michael J Crescenz Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA.

Department of Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Centre for Age-Related Disease, Stavanger University Hospital, Stavanger, Norway.

出版信息

Lancet Neurol. 2022 Jan;21(1):89-102. doi: 10.1016/S1474-4422(21)00330-6.

Abstract

In people with Parkinson's disease, neuropsychiatric signs and symptoms are common throughout the disease course. These symptoms can be disabling and as clinically relevant as motor symptoms, and their presentation can be similar to, or distinct from, their counterparts in the general population. Correlates and risk factors for developing neuropsychiatric signs and symptoms include demographic, clinical, and psychosocial characteristics. The underlying neurobiology of these presentations is complex and not well understood, with the strongest evidence for neuropathological changes associated with Parkinson's disease, mechanisms linked to dopaminergic therapy, and effects not specific to Parkinson's disease. Assessment instruments and formal diagnostic criteria exist, but there is little routine screening of these signs and symptoms in clinical practice. Mounting evidence supports a range of pharmacological and non-pharmacological interventions, but relatively few efficacious treatment options exist. Optimising the management of neuropsychiatric presentations in people with Parkinson's disease will require additional research, raised awareness, specialised training, and development of innovative models of care.

摘要

在帕金森病患者中,神经精神症状在整个病程中都很常见。这些症状可能使人丧失能力,与运动症状一样具有临床相关性,其表现可能与普通人群中的症状相似或不同。出现神经精神症状的相关因素和风险因素包括人口统计学、临床和社会心理特征。这些表现的潜在神经生物学机制复杂且尚未完全理解,与帕金森病相关的神经病理学变化、与多巴胺能治疗相关的机制以及与帕金森病无关的影响的证据最强。目前已经存在评估工具和正式的诊断标准,但在临床实践中很少对这些症状进行常规筛查。越来越多的证据支持一系列药物和非药物干预措施,但有效的治疗选择相对较少。优化帕金森病患者神经精神表现的管理将需要更多的研究、提高认识、专门培训和创新的护理模式的发展。

相似文献

1
The neuropsychiatry of Parkinson's disease: advances and challenges.
Lancet Neurol. 2022 Jan;21(1):89-102. doi: 10.1016/S1474-4422(21)00330-6.
2
Parkinson's disease.
Lancet. 2021 Jun 12;397(10291):2284-2303. doi: 10.1016/S0140-6736(21)00218-X. Epub 2021 Apr 10.
3
The site of stimulation moderates neuropsychiatric symptoms after subthalamic deep brain stimulation for Parkinson's disease.
Neuroimage Clin. 2018 Mar 13;18:996-1006. doi: 10.1016/j.nicl.2018.03.009. eCollection 2018.
4
Neuropsychiatric manifestations of Parkinson's disease.
Australas Psychiatry. 2016 Dec;24(6):529-533. doi: 10.1177/1039856216654393. Epub 2016 Jul 25.
5
Commentary on "The Neuropsychiatry of Parkinson's Disease: A Perfect Storm".
Am J Geriatr Psychiatry. 2019 Sep;27(9):1019-1021. doi: 10.1016/j.jagp.2019.03.007. Epub 2019 Mar 20.
6
Management of psychiatric and cognitive complications in Parkinson's disease.
BMJ. 2022 Oct 24;379:e068718. doi: 10.1136/bmj-2021-068718.
7
Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
Brain. 2017 Jul 1;140(7):1959-1976. doi: 10.1093/brain/awx118.
8
Neuropsychiatric Symptoms in Parkinson's Disease.
J Parkinsons Dis. 2015;5(3):659-67. doi: 10.3233/JPD-150604.
9
Treatment options for non-motor symptoms in late-stage Parkinson's disease.
Expert Opin Pharmacother. 2008 Mar;9(4):523-35. doi: 10.1517/14656566.9.4.523.

引用本文的文献

1
Validation of the English version of the Parkinson Anxiety Scale in two Canadian Parkinson's disease samples.
Clin Park Relat Disord. 2025 Aug 9;13:100387. doi: 10.1016/j.prdoa.2025.100387. eCollection 2025.
2
Acupuncture for Parkinson's Disease: A Narrative Review of Clinical Efficacy and Mechanistic Insights.
Neuropsychiatr Dis Treat. 2025 Aug 22;21:1731-1750. doi: 10.2147/NDT.S532027. eCollection 2025.
5
An Interdisciplinary Approach to Assistive Technology for Parkinson's Disease Dementia.
Clin Interv Aging. 2025 Aug 15;20:1253-1265. doi: 10.2147/CIA.S516786. eCollection 2025.
7
Neuropsychiatric disorders in Parkinson's disease.
Ther Adv Neurol Disord. 2025 Jul 28;18:17562864251356062. doi: 10.1177/17562864251356062. eCollection 2025.
9
Research progress of assessment tools for Parkinson's disease psychosis in China.
Front Psychiatry. 2025 Jul 10;16:1588618. doi: 10.3389/fpsyt.2025.1588618. eCollection 2025.

本文引用的文献

1
Trial of Pimavanserin in Dementia-Related Psychosis.
N Engl J Med. 2021 Jul 22;385(4):309-319. doi: 10.1056/NEJMoa2034634.
3
Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment.
Mov Disord. 2021 Nov;36(11):2549-2558. doi: 10.1002/mds.28548. Epub 2021 Mar 12.
4
Parkinson's Disease Subtypes: Critical Appraisal and Recommendations.
J Parkinsons Dis. 2021;11(2):395-404. doi: 10.3233/JPD-202472.
6
Evolution of Apathy in Early Parkinson's Disease: A 4-Years Prospective Cohort Study.
Front Aging Neurosci. 2021 Jan 28;12:620762. doi: 10.3389/fnagi.2020.620762. eCollection 2020.
7
Networks Are Associated With Depression in Patients With Parkinson's Disease: A Resting-State Imaging Study.
Front Neurosci. 2021 Feb 9;14:573538. doi: 10.3389/fnins.2020.573538. eCollection 2020.
8
Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial.
Mov Disord. 2021 Nov;36(11):2539-2548. doi: 10.1002/mds.28533. Epub 2021 Feb 22.
9
Association Between BDNF Val66Met Polymorphism and Mild Behavioral Impairment in Patients With Parkinson's Disease.
Front Neurol. 2021 Jan 14;11:587992. doi: 10.3389/fneur.2020.587992. eCollection 2020.
10
Depression and Nigral Neuron Density in Lewy Body Spectrum Diseases.
Ann Neurol. 2021 May;89(5):1046-1050. doi: 10.1002/ana.26046. Epub 2021 Mar 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验